Cargando…
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation
BACKGROUND: Tumor hypoxia worsens the prognosis of head-and-neck squamous cell carcinoma (HNSCC) patients, and plasma hypoxia markers may be used as biomarkers for radiotherapy personalization. We therefore investigated the role of the hypoxia-associated plasma proteins osteopontin, galectin-3, vasc...
Autores principales: | Rühle, Alexander, Grosu, Anca-L., Wiedenmann, Nicole, Ruf, Juri, Bieber, Birgit, Stoian, Raluca, Thomsen, Andreas R., Gkika, Eleni, Vaupel, Peter, Baltas, Dimos, Weber, Wolfgang A., Mix, Michael, Nicolay, Nils H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881198/ https://www.ncbi.nlm.nih.gov/pubmed/35243023 http://dx.doi.org/10.1016/j.ctro.2022.02.008 |
Ejemplares similares
-
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial
por: Rühle, Alexander, et al.
Publicado: (2021) -
Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation
por: Rühle, Alexander, et al.
Publicado: (2020) -
(18)F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy
por: Carles, Montserrat, et al.
Publicado: (2021) -
Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022) -
Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients
por: Sprave, Tanja, et al.
Publicado: (2022)